跳至主要内容
临床试验/CTRI/2024/03/064000
CTRI/2024/03/064000尚未招募3 期

Efficacy and Safety of Levetiracetam in Episodic Migraine Prophylaxis: A Randomized Double Blind Placebo Controlled Trial - Nil

JIPMER, Puducherry0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patients with episodic migraine [having
  • fewer than 15 monthly attacks of unilateral, pulsating, moderate/severe headache lasting 4-72 hours that is aggravated by physical activity associated with nausea, and/or photophobia and phonophobia and in some cases preceded by fully reversible CNS symptoms (aura)] where prophylaxis is indicated.
  • 2. Aged 18-50 years
  • 3. Not receiving any other prophylactic medi-
  • cation for past one month.
  • 4. Episodic migraine should be present for at
  • least 12 months prior to evaluation for study inclusion

排除标准

  • 1. Patients who have chronic migraine (at least
  • 15 headache days/month with a minimum of 8 migraine days/month for at least 3 months
  • 2. Non Migraine headaches (trigeminal autonomic cephalalgias, neuralgias, secondary headache)
  • 3. Pregnant and lactating female patients, or
  • plans to become pregnant during the study period
  • 4. Subjects who are overusing alcohol or using
  • illicit drugs as per DSM V
  • 5. Patients with other co-morbidities like epilepsy,and other major illness

研究者

相似试验